Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer

Table 2 Associations between ACLY gene genotypes and clinical outcomes of CRC patients

Patients/SNPs	Genotypes	OS			RFS
Patients/SNPs	Genotypes	Death/all	HR ^a (95% CI)	P value	Recurrence/all	HR ^a (95% CI)	P value
In all patients
rs2304497	WW	173/578	Ref.		203/578	Ref.
	WV + VV	29/111	0.87(0.59–1.29)	0.49	34/111	0.85(0.59–1.23)	0.39
rs9912300	WW	140/461	Ref.		165/461	Ref.
	WV + VV	63/229	0.87(0.64–1.17)	0.35	73/229	0.81(0.61–1.07)	0.13
In patients with early stage (I + II)
rs2304497	WW	74/370	Ref.		94/370	Ref.
	WV + VV	19/76	1.32(0.79–2.19)	0.29	23/76	1.20(0.75–1.90)	0.45
rs9912300	WW	56/292	Ref.		72/292	Ref.
	WV + VV	38/155	1.28(0.84–1.94)	0.25	46/155	1.15(0.79–1.67)	0.47
In patients with advanced stage (III + IV)
rs2304497	WW	99/208	Ref.		109/208	Ref.
	WV + VV	10/35	0.47(0.24–0.90)	0.02	11/35	0.46(0.24–0.86)	0.02
rs9912300	WW	84/169	Ref.		93/169	Ref.
	WV + VV	25/74	0.59(0.37–0.92)	0.02	27/74	0.54(0.35–0.83)	0.01

Significant P values (<0.05) are in italics.
Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival; RFS, recurrence free survival; Ref., reference.
^aAdjusted by gender, age, hospital site, tumor position, TNM stage, tumor differentiation, and treatment after surgery where appropriate.

ISSN: 1477-7819